THRD Stock Price, Third Harmonic Bio Inc Quote, Chart

Market Summary

USD13.85-0.38

Delayed

-2.67%

THRD Alerts

1 major insider sales recently.

THRD Stock Price

View Fullscreen

THRD RSI Chart

THRD Valuation

Market Cap

567.2M

Price/Earnings (Trailing)

-19.16

Price/Free Cashflow

-28.06

THRD Price/Earnings (Trailing)

THRD Profitability

Return on Equity

-11.23%

Return on Assets

-10.94%

Free Cashflow Yield

-3.56%

THRD Fundamentals

THRD Earnings

Earnings (TTM)

-29.6M

Earnings Growth (Yr)

13.53%

Earnings Growth (Qtr)

-14.92%

Breaking Down THRD Revenue

Last 7 days

16.4%

Last 30 days

22.8%

Last 90 days

37.5%

How does THRD drawdown profile look like?

THRD Financial Health

Current Ratio

66.1

THRD Investor Care

Shares Dilution (1Y)

1.45%

Diluted EPS (TTM)

0.75

Tracking the Latest Insider Buys and Sells of Third Harmonic Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 09, 2024	holles natalie c.	acquired	84,932	4.2	20,222	ceo
May 09, 2024	holles natalie c.	sold	-246,300	12.1798	-20,222	ceo
Apr 11, 2024	holles natalie c.	acquired	56,943	4.2	13,558	ceo
Apr 11, 2024	holles natalie c.	sold	-165,214	12.1857	-13,558	ceo
Apr 04, 2024	person julie	acquired	4,649	4.2	1,107	chief administrative officer
Apr 04, 2024	person julie	sold	-11,070	10.00	-1,107	chief administrative officer
Dec 05, 2023	conner edward r.	sold	-48,062	10.0339	-4,790	chief medical officer
Dec 05, 2023	conner edward r.	acquired	20,118	4.2	4,790	chief medical officer
Dec 05, 2023	person julie	acquired	54,024	4.2	12,863	chief administrative officer
Dec 05, 2023	person julie	sold	-132,484	10.2996	-12,863	chief administrative officer

Which funds bought or sold THRD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	81.4	74,697	207,840	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.9	-16,677	18,493	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	-8,841,980	54,554,400	1.00%
May 15, 2024	Parkman Healthcare Partners LLC	new	-	377,600	377,600	0.05%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	new	-	134,284	134,284	0.02%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-5.93	-49,554	210,588	-%
May 15, 2024	COMMODORE CAPITAL LP	reduced	-11.56	-3,705,130	11,800,000	0.79%
May 15, 2024	HSBC HOLDINGS PLC	new	-	113,063	113,063	-%
May 15, 2024	BRAIDWELL LP	sold off	-100	-14,436,700	-	-%
May 15, 2024	MORGAN STANLEY	reduced	-32.38	-882,675	1,228,510	-%

Are Funds Buying or Selling THRD?

Are funds buying THRD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own THRD

No. of Funds

THRD Alerts

1 major insider sales recently.

Unveiling Third Harmonic Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	7.9%	3,182,444	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0%	0	SC 13G/A
Nov 27, 2023	ra capital management, l.p.	5%	2,033,056	SC 13G

Recent SEC filings of Third Harmonic Bio Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 10, 2024	4	Insider Trading
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 15, 2024	4	Insider Trading
Apr 11, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Third Harmonic Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Third Harmonic Bio Inc News

Latest updates

Third Harmonic Bio Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet								(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4
Assets	-2.6%	271	278	282	286	291	299	305	129
Current Assets	-2.5%	266	272	277	280	286	293	304	129
Cash Equivalents	-2.3%	263	269	274	278	282	289	300	128
Net PPE	-7.1%	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Liabilities	-18.6%	7.00	9.00	9.00	8.00	9.00	10.00	6.00	6.00
Current Liabilities	-25.8%	4.00	5.00	6.00	4.00	5.00	6.00	6.00	6.00
Shareholder's Equity	-2.1%	264	269	273	278	283	289	298	-46.71
Retained Earnings	-6.9%	-122	-114	-107	-100	-92.50	-83.40	-71.90	-48.24
Additional Paid-In Capital	0.6%	386	383	380	378	375	372	370	2.00
Shares Outstanding	1.5%	41.00	40.00	40.00	40.00	39.00	39.00	9.00	4.00
Float	-	-	-	-	86.00	-	-	388	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-12.2%	-6,293	-5,607	-4,183	-3,960	-6,675	-9,287	-10,778	-6,739	-8,113	-	-
Share Based Compensation	26.4%	2,223	1,759	2,291	2,845	2,682	2,133	1,009	1,159	450	-	-
Cashflow From Investing	100.0%	-	-1.00	-	-168	-	-36.00	-	-	-	-	-
Cashflow From Financing	-93.9%	49.00	798	-57.00	58.00	-	-875	197,563	-697	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

THRD Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 6,226	$ 6,737
General and administrative	5,064	5,251
Total operating expenses	11,290	11,988
Loss from operations	11,290	11,988
Other income, net:
Interest income	(3,433)	(2,905)
Other (income) expense	(1)	2
Total other income, net	(3,434)	(2,903)
Net loss	$ 7,856	$ 9,085
Net loss per share of common stock, basic	$ 0.2	$ 0.23
Net loss per share of common stock, diluted	$ 0.2	$ 0.23
Weighted-average number of common stock outstanding, basic	40,213,158	39,438,572
Weighted-average number of common stock outstanding, diluted	40,213,158	39,438,572

THRD Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 262,826	$ 269,070
Prepaid expenses and other current assets	2,771	3,376
Total current assets	265,597	272,446
Restricted cash	453	453
Property and equipment, net	157	169
Right of use asset	3,589	3,763
Other assets, noncurrent	725	880
Total assets	270,521	277,711
Current liabilities:
Accounts payable	945	1,838
Accrued expenses and other current liabilities	2,300	2,835
Operating lease liability, current	773	745
Total current liabilities	4,018	5,418
Operating lease liability, noncurrent	3,002	3,208
Total liabilities	7,020	8,626
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock, $0.0001 par value, 500,000,000 shares authorized at December 31, 2023 and March 31, 2024; 40,104,937 and 40,252,868 shares issued and outstanding at December 31, 2023 and March 31, 2024, respectively	4	4
Additional paid-in capital	385,573	383,301
Accumulated deficit	(122,076)	(114,220)
Total stockholders' equity	263,501	269,085
Total liabilities and stockholders' equity	$ 270,521	$ 277,711

About Third Harmonic Bio Inc

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Natalie C. Holles
WEBSITE	thirdharmonicbio.com
INDUSTRY	Biotechnology
EMPLOYEES	31

Third Harmonic Bio Inc Frequently Asked Questions

What is the ticker symbol for Third Harmonic Bio Inc? What does THRD stand for in stocks?

THRD is the stock ticker symbol of Third Harmonic Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Third Harmonic Bio Inc (THRD)?

As of Fri May 17 2024, market cap of Third Harmonic Bio Inc is 567.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of THRD stock?

You can check THRD's fair value in chart for subscribers.

What is the fair value of THRD stock?

You can check THRD's fair value in chart for subscribers. The fair value of Third Harmonic Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Third Harmonic Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for THRD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Third Harmonic Bio Inc a good stock to buy?

The fair value guage provides a quick view whether THRD is over valued or under valued. Whether Third Harmonic Bio Inc is cheap or expensive depends on the assumptions which impact Third Harmonic Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for THRD.